Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Previous Page Next Page

PARP inhibitors have been approved for use in breast cancer subtypes that exhibit homologous recombination deficiency (HRD) and ovarian cancer irrespective of HRD status. Because HRD is observed in many tumour types other than ovarian and breast cancer [1-3], PARP inhibition is also being explored in several other tumour types including prostate, pancreatic, lung, gastric and several other cancers. For many of these indications, stratifying patients with HRD seems key to improving treatment outcomes.

Clinical activity is often assessed using intermediate endpoints between progression-free survival and overall survival. Click here to find out more use about intermediate endpoints.

Intermediate endpoints

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings